Table 4. Odds ratios (ORs) and 95% confidence intervals (CIs) of herpes zoster (HZ) among the patients who received R-CHOP/R-CEOP or CHOP/CEOP during the 1-, 2-, and 7-year follow-up periods.
| 1-year follow-up period | 2-year follow-up period | 7-year follow-up period | ||||
|---|---|---|---|---|---|---|
| HZ | R-CHOP/R-CEOP | CHOP/CEOP | R-CHOP/R-CEOP | CHOP/CEOP | R-CHOP/R-CEOP | CHOP/CEOP |
| Yes (n, %) | 131(8.28) | 97 (6.13) | 178(11.25) | 134(8.47) | 203(12.83) | 176(11.12) |
| No (n, %) | 1451(91.72) | 1485(93.87) | 1404(88.75) | 1448(91.53) | 1379(87.17) | 1406(88.88) |
| Crude OR (95% CI) | 1.38a(1.05–1.82) | 1 | 1.37c(1.08–1.73) | 1 | 1.18e(0.95–1.46) | 1 |
| Adjust OR (95% CI) | 1.38b(1.05–1.81) | 1 | 1.37d(1.08–1.73) | 1 | 1.17f(0.95–1.46) | 1 |
*Adjustments were made for the patients’ genders, ages and Charlson comorbidity indices.
(P-values: a: 0.020; b: 0.021; c: 0.009; d: 0.010; e: 0.140; and f: 0.148).
R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CEOP, cyclophosphamide, epirubicin, vincristine, prednisolone.